Carl Goldfischer, MD Bay City Capital

Carl Goldfischer, MD, is an Investment Partner and Managing Director of Bay City Capital, serving as a member of the board of directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Dr. Goldfischer serves on the board of directors of numerous companies, including: BrainCells, EnteroMedics, Epizyme and Metabolex. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College.

Bruce Scharschmidt, MD Independent Director

Bruce Scharschmidt, MD, was most recently Sr. VP & Chief Medical & Development Officer at Hyperion Therapeutics, where he was responsible for the development of RAVICTI®, which was approved for the treatment urea cycle disorders in February, 2013. He was a member of Hyperion’s road show team leading to its 2012 IPO, 2013 secondary offering and May 2015 sale of the company to Horizon Pharma, to which he remains a consultant. Previously he held senior positions at Novartis, Chiron and the Univ. of CA, San Francisco, where he was Chief of Gastroenterology, Prof of Medicine and an NIH-funded investigator for two decades. He is author of over 200 research and review articles and served as Associate Editor of Gastroenterology, Editor-in-Chief of the Journal of Clinical Investigation, and President of the American Society for Clinical Investigation. Board Certified in Internal Medicine and Gastroenterology, he is on the Scientific Advisory Board for the Clinical and Translational Science Program at Northwestern/Feinberg School of Medicine, President of Northwestern’s Medical Alumni Board, a member of the National Board of Directors of the Am Liver Foundation from 2005-2013 and prior Chair of the Translational Team for the J David Gladstone Institute, where he is member of the President’s Council Executive Committee.

Mervyn J. Turner, PhD  Bay City Capital

Dr. Mervyn Turner has over 25 years of experience in pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets, strategy development and implementation. In his last role prior to his retirement from Merck & Co. Inc., he was the company's first Chief Strategy Officer, and drove strategy planning and resource planning discussions. He also worked with the research division, the commercial organization and the manufacturing division to develop a coherent, overarching strategy for Merck & Co. Inc.'s investments in the emerging markets. Prior to that, he was head of World Wide Licensing & External Research and was personally involved in more than 200 strategic transactions, including mergers and acquisitions. Dr. Turner has published over 80 articles in peer reviewed journals.

Rupert Vessey, MA – Celgene

Robert F. Williamson, III, MBA  PharmAkea

Robert F. Williamson, III is the CEO of PharmAkea. He has been involved in starting and assisting public and private companies through his consultancy, LaSalle Venture Advisers. He was recently acting CEO of BrainCells Inc. and Executive Chairman of privately held Strategic Enzyme Applications, Inc. (SEA). Previously, he was on the board of Pharmasset, Inc. (NASDAQ: VRUS) which was bought by Gilead (NASDAQ:GILD) for $11B and was on the board of Progen Pharmaceuticals (NASDAQ: PGLA) after he sold CellGate to Progen. He was also Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology - which he sold to Protein Design Labs (NASDAQ: PDLI), and Chief Operating Officer of Pangea / DoubleTwist, Inc. - which was acquired in part by Merck (NYSE: MRK) and Hitachi (NYSE: HIT). Before managing life sciences companies, Mr. Williamson was a partner with The Boston Consulting Group, Inc., and his clients included top pharmaceutical, medical device and health care companies with additional clients in high technology and energy. Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, D.C. He received a B.A. in Economics from Pomona College and an M.B.A. from Stanford Graduate School of Business.